Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

234
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
234
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

181
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
181
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Swelling of the Left Upper Limb with Red Papules, Necrosis and Crusting: A Quiz.

Acta dermato-venereologica·2026
Same author

Laboratory Parameters Can Serve as Objective Auxiliary Tools for Assessing Disease Severity in Hidradenitis Suppurativa: A 5-Year Period Single-Center Retrospective Study.

Clinical, cosmetic and investigational dermatology·2026
Same author

Phenotype-dependent effects of IL-17A inhibitors on lipid profiles in moderate-to-severe plaque psoriasis: a retrospective cohort study.

Lipids in health and disease·2026
Same author

Decreased HDL-C in hidradenitis suppurativa: association with systemic inflammatory phenotype and implications for risk stratification.

Lipids in health and disease·2026
Same author

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients.

The Journal of dermatological treatment·2025
Same author

Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach.

Psoriasis (Auckland, N.Z.)·2025

Related Experiment Video

Updated: Aug 14, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Biologics in pediatric psoriasis.

Wen-Ming Wang1, Hong-Zhong Jin1

  • 1Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

The Journal of Dermatology
|January 18, 2023
PubMed
Summary

Biologics offer effective psoriasis treatment for children. Real-world data and clinical trials suggest anti-interleukin-12/23 (IL-12/23) and anti-interleukin-17A (IL-17A) may outperform anti-tumor necrosis factor-alpha (TNF-α) therapies.

Keywords:
biologicspediatric psoriasisplaque psoriasisreal-world studies

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.2K
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

14.7K

Related Experiment Videos

Last Updated: Aug 14, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.2K
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

14.7K

Area of Science:

  • Dermatology
  • Immunology
  • Pediatric Medicine

Background:

  • Psoriasis is a chronic inflammatory skin condition with frequent relapses.
  • Biologic therapies have significantly improved adult psoriasis treatment outcomes.
  • There is growing interest and approval for biologics in pediatric psoriasis management.

Purpose of the Study:

  • To review real-world evidence and clinical trial data on biologic use in pediatric psoriasis.
  • To evaluate the efficacy and safety of different biologic agents in children with psoriasis.
  • To compare the effectiveness of various biologic classes in treating pediatric psoriasis.

Main Methods:

  • Systematic review of real-world studies and clinical trials concerning biologics for pediatric psoriasis.
  • Exclusion of case reports to focus on aggregated data.
  • Analysis of efficacy and safety data from approved biologic therapies.

Main Results:

  • Biologics demonstrate encouraging efficacy in treating pediatric psoriasis.
  • Real-world studies and clinical trials indicate potential superiority of anti-IL-12/23 and anti-IL-17A agents.
  • Anti-tumor necrosis factor-alpha (TNF-α) therapies are also utilized, but comparative data suggests other agents may be more effective.

Conclusions:

  • Biologics are a valuable treatment option for pediatric psoriasis.
  • Emerging data suggests anti-IL-12/23 and anti-IL-17A biologics may offer enhanced efficacy compared to anti-TNF-α agents in children.
  • Further research and data collection are necessary to confirm these findings and optimize treatment strategies.